Literature DB >> 11892067

Hematopoietic stem cell transplantation for severe combined immune deficiency.

K I Weinberg1, N Kapoor, A J Shah, G M Crooks, D B Kohn, R Parkman.   

Abstract

Hematopoietic stem cell transplantation (HSCT) has been the definitive therapy for severe combined immune deficiency (SCID) since the first successful transplant for SCID in 1968. Improvements in the use of HSCT to treat patients with SCID are continuing. For example, during the last 5 years, the first successful in-utero HSCT, and the first success with gene therapy have occurred in patients with SCID. Debate still continues about the role of pretransplantation therapy for SCID patients, and the biology of post-HSCT immune reconstitution is under investigation.

Entities:  

Mesh：

Year:  2001        PMID： 11892067     DOI： 10.1007/s11882-001-0026-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN： 1529-7322            Impact factor:   4.806


  38 in total

Review 1.  In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers.

Authors:  A W Flake; E D Zanjani
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

2.  Intrinsic defects of B cell function in X-linked severe combined immunodeficiency.

Authors:  H White; A Thrasher; P Veys; C Kinnon; H B Gaspar
Journal:  Eur J Immunol       Date:  2000-03       Impact factor: 5.532

3.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients.

Authors:  J Kurtzberg; M Laughlin; M L Graham; C Smith; J F Olson; E C Halperin; G Ciocci; C Carrier; C E Stevens; P Rubinstein
Journal:  N Engl J Med       Date:  1996-07-18       Impact factor: 91.245

4.  Combined immunodeficiency disease associated with absence of cell-surface HLA-A and -B antigens.

Authors:  J L Touraine; H Betuel; G Souillet; M Jeune
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

5.  Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation.

Authors:  B Horn; M Viele; W Mentzer; N Mogck; K DeSantes; M Cowan
Journal:  Bone Marrow Transplant       Date:  1999-11       Impact factor: 5.483

6.  Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: A single-center study of 22 patients.

Authors:  E Haddad; F Le Deist; P Aucouturier; M Cavazzana-Calvo; S Blanche; G De Saint Basile; A Fischer
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

7.  Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow.

Authors:  A W Flake; M G Roncarolo; J M Puck; G Almeida-Porada; M I Evans; M P Johnson; E M Abella; D D Harrison; E D Zanjani
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

8.  Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2.

Authors:  K Welte; N Ciobanu; M A Moore; S Gulati; R J O'Reilly; R Mertelsmann
Journal:  Blood       Date:  1984-08       Impact factor: 22.113

9.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

Review 10.  Chronic enteroviral meningoencephalitis in agammaglobulinemic patients.

Authors:  R E McKinney; S L Katz; C M Wilfert
Journal:  Rev Infect Dis       Date:  1987 Mar-Apr
View more
  1 in total

1.  Prognostic potential of precise molecular diagnosis of Autosomal Recessive Osteopetrosis with respect to the outcome of bone marrow transplantation.

Authors:  Anna Villa; Alessandra Pangrazio; Elena Caldana; Matteo Guerrini; Paolo Vezzoni; Annalisa Frattini; Cristina Sobacchi
Journal:  Cytotechnology       Date:  2008-09-30       Impact factor: 2.058
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.